DelveInsight’s “Exosomes Pipeline Insights 2026” Report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in Exosomes pipeline landscape. It covers the Exosomes pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Exosomes pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Dive into DelveInsight’s comprehensive report today! @ Exosomes Pipeline Report
Key Takeaways from the Exosomes Pipeline Report
- DelveInsight’s Exosomes pipeline report depicts a robust space with 100+ active players working to develop 110+ pipeline therapies for Exosomes applications.
- The leading Exosomes Companies such as Capricor Therapeutics, BrainStorm Cell Therapeutics, Aegle Therapeutics, EXO Biologics, RION, S&E bio, Shine-On Biomedical Co., Ltd., ImmVira, ILIAS Biologics, Secretome Therapeutics, VesiCURE Therapeutics, Everzom, Brexogen, ShiftBio, Conveyxo, Exogenus Therapeutics, Coya Therapeutics, VivaZome Therapeutics, NurExone, Ji Yan Biomedical Co., Ltd., and others.
- Promising Exosomes Pipeline Therapies such as CAP-1002, Debamestrocel, AGLE-102, EXOB-001, RioMSK001, SNE-101, SOB 100, MVR-EX101, ILB 202, STM-01, MDX-101, EViv, BRE-NA01, SBI-101, EXOSTEO01, Exo–101, COYA 201, VZT-PEV, ExoPTEN therapy, ExoVeris, and others.
Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Exosomes Treatment Drugs
The Exosomes Pipeline Report provides overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Exosomes Pipeline Report also highlights the unmet needs with respect to Exosomes applications.
Exosomes Overview
Exosomes are small extracellular vesicles (≈40–160 nm) released by most cell types through the fusion of multivesicular bodies with the plasma membrane, which liberates intraluminal vesicles into the extracellular space. They are widely present in biological fluids such as blood, urine, breast milk, and semen, and can be taken up by distant cells. Through the transfer of bioactive cargo, exosomes play a crucial role in cell–cell communication and can influence disease progression. Their contents including proteins, lipids, nucleic acids, amino acids, and metabolites reflect their cell of origin and are shaped during their biogenesis in the endosomal pathway.
Exosomes are formed through a double invagination process of the plasma membrane, leading to the creation of multivesicular bodies (MVBs) that contain intraluminal vesicles (ILVs), which are later released as exosomes upon fusion with the plasma membrane. Their biogenesis is tightly regulated by proteins such as ESCRT complexes, Rab GTPases, ALIX, and tetraspanins, which facilitate cargo sorting, membrane budding, and vesicle release. Exosomes carry diverse biomolecules including DNA, RNA, proteins, lipids, and metabolites reflecting their cell of origin and functional state.
Exosomes are being widely investigated for both diagnostic and therapeutic applications due to their complex molecular cargo and natural role in intercellular communication. As they are present in nearly all biological fluids, they offer a minimally invasive “liquid biopsy” approach for disease detection and monitoring across conditions such as cancer, cardiovascular, neurological, and organ-specific diseases. Therapeutically, exosomes exhibit excellent biocompatibility, low immunogenicity, and efficient biodistribution, enabling targeted delivery of functional biomolecules to diseased cells. They can also serve as natural drug delivery vehicles, capable of crossing biological barriers like the blood–brain barrier and delivering payloads such as RNA or drugs with reduced toxicity.
Exosomes Emerging Drugs Profile
CAP-1002: Capricor Therapeutics
Capricor’s CAP-1002 consists of cardiosphere-derived cells (CDCs), a type of cardiac progenitor cell originally discovered in the laboratory of its scientific founder, Eduardo Marbán. These CDCs have been extensively studied, with over 100 peer-reviewed publications and clinical administration in more than 200 patients across multiple trials. CAP-1002 works by releasing exosomes, small vesicles that influence immune responses and promote tissue repair. These exosomes are primarily taken up by macrophages and T cells, triggering regenerative processes and modulating immune activity. The therapy is currently in the registration stage for the treatment of Duchenne Muscular Dystrophy.
Debamestrocel: BrainStorm Cell Therapeutics
Debamestrocel (NurOwn) consists of autologous bone marrow–derived mesenchymal stem cells (MSCs) that are cultured to secrete elevated levels of neurotrophic factors, supporting neuronal survival and repair. These MSC-NTF cells combine the immunomodulatory effects of MSCs with enhanced neurotrophic activity, partly mediated through exosome-based delivery of factors such as GDNF. The therapy is manufactured from a patient’s own MSCs, expanded and differentiated ex vivo without genetic modification, and then re-administered. It is currently in Phase III development for the treatment of Amyotrophic Lateral Sclerosis, with additional programs in multiple neurological disorders at earlier stages.
AGLE-102: Aegle Therapeutics
AGLE-102 is an allogeneic extracellular vesicle (EV) therapy derived from mesenchymal stem cells obtained from healthy donors. It consists of MSC-derived vesicles that deliver proteins, genetic material, and regenerative factors to support repair in damaged tissues. The therapy is currently in Phase I/II development for the treatment of burns and Epidermolysis Bullosa Dystrophica, and is also being explored at the preclinical stage for Graft-versus-Host Disease.
RioMSK001: RION
RioMSK001 is an innovative therapeutic candidate developed by Rion for musculoskeletal disorders. It is designed to address degenerative joint conditions with a focus on improving function and reducing disease burden. According to the company’s pipeline, the therapy is currently in early clinical evaluation. It is in Phase I development for the treatment of Knee Osteoarthritis.
HEPATOSOME: ExoStemTech
HEPATOSOME is an investigational therapy being developed by ExoStemTech. It is designed as a novel approach targeting liver-related disorders through advanced therapeutic mechanisms. The candidate is currently undergoing early-stage research and evaluation. At present, it is in preclinical development for the treatment of Liver Fibrosis.
The Exosomes Pipeline Report Provides Insights into
- The report provides detailed insights about companies that are developing therapies utilizing Exosomes with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Exosomes-based Treatment.
- Exosomes Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Exosomes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Exosomes market.
Explore groundbreaking therapies and clinical trials in the Exosomes Pipeline @ New Exosomes Drugs
Exosomes Companies
Capricor Therapeutics, BrainStorm Cell Therapeutics, Aegle Therapeutics, EXO Biologics, RION, S&E bio, Shine-On Biomedical Co., Ltd., ImmVira, ILIAS Biologics, Secretome Therapeutics, VesiCURE Therapeutics, Everzom, Brexogen, ShiftBio, Conveyxo, Exogenus Therapeutics, Coya Therapeutics, VivaZome Therapeutics, NurExone, Ji Yan Biomedical Co., Ltd., and others.
Exosomes Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Exosomes Products have been categorized under various Molecule types such as:
- Recombinant fusion proteins
- Small molecule
- Monoclonal Antibody
- Peptide
- Polymer
- Gene therapy
Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Exosomes Market Drivers and Barriers
Scope of the Exosomes Pipeline Report
- Coverage- Global
- Exosomes Companies- Capricor Therapeutics, BrainStorm Cell Therapeutics, Aegle Therapeutics, RION, S&E bio, Shine-On Biomedical Co., Ltd., ImmVira, ILIAS Biologics, Secretome Therapeutics, VesiCURE Therapeutics, Everzom, Brexogen, ShiftBio, Conveyxo, Exogenus Therapeutics, Coya Therapeutics, VivaZome Therapeutics, NurExone, Ji Yan Biomedical Co., Ltd., and others.
- Exosomes Pipeline Therapies- CAP-1002, Debamestrocel, AGLE-102, EXOB-001, RioMSK001, SNE-101, SOB 100, MVR-EX101, ILB 202, STM-01, MDX-101, EViv, BRE-NA01, SBI-101, EXOSTEO01, Exo–101, COYA 201, VZT-PEV, ExoPTEN therapy, ExoVeris, and others.
- Exosomes Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Exosomes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III, Registration
Get the latest on Exosomes Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Exosomes Companies, Key Products and Unmet Needs
Table of Contents
- Introduction
- Executive Summary
- Exosomes: Overview
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Exosomes – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Mid Stage Products (Phase II)
- Early Stage Products (Phase I)
- Preclinical and Discovery Stage Products
- Inactive Products
- Exosomes Key Companies
- Exosomes Key Products
- Exosomes – Unmet Needs
- Exosomes – Market Drivers and Barriers
- Exosomes – Future Perspectives and Conclusion
- Exosomes Analyst Views
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Kanishk
